Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.
Elisa FarinaAlessandro LoglioGiulia TosettiElisabetta DegasperiMauro ViganòCarmine GentileSara MonicoRiccardo PerbelliniMarta BorghiFloriana FacchettiSara Colonia Uceda RenteriaFerruccio CeriottiFederica CeriniMassimo PrimignaniPietro LamperticoPublished in: Alimentary pharmacology & therapeutics (2023)
In compensated cirrhotic patients under long-term effective TDF/ETV treatment, the 11-year risk of developing/progressing EV is negligible, thus challenging the current endoscopic surveillance recommendations in patients without EV at baseline.